Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain

  • Naoaki Fujii
  • , Jeremy P. Mallari
  • , Elizabeth J. Hansell
  • , Z. MacKey
  • , Patricia Doyle
  • , Y. M. Zhou
  • , Jiri Gut
  • , Philip J. Rosenthal
  • , James H. McKerrow
  • , R. Kiplin Guy

Producción científica: Article › revisión exhaustiva

159 Citas (Scopus)

Resumen

Herein we report the synthesis and evaluation of a series of thiosemicarbazones as potential inhibitors of cysteine proteases relevant to parasitic diseases. Derivatives of thiosemicarbazone 1 were discovered to be potent inhibitors of cruzain and rhodesain, crucial proteases in the life cycles of Trypanosoma cruzi and T. brucei rhodesiense, the organisms causing Chagas' disease and sleeping sickness. However, the entire series had only modest potency against falcipain-2, an essential protease for Plasmodium falciparum, the organism causing malaria. Among the active inhibitors, several potently inhibited proliferation of cultures of T. brucei. However, only modest activity was observed in inhibition of proliferation of T. cruzi or P. falciparum. Herein we report the synthesis and evaluation of a series of thiosemicarbazones as potential inhibitors of cysteine proteases relevant to parasitic diseases. Derivatives of thiosemicarbazone 1 were discovered to be potent inhibitors of cruzain and rhodesain, crucial proteases in the life cycles of Trypanosoma cruzi and T. brucei rhodesiense, the organisms causing Chagas' disease and sleeping sickness. However, the entire series had only modest potency against falcipain-2, an essential protease for Plasmodium falciparum, the organism causing malaria. Among the active inhibitors, several potently inhibited proliferation of cultures of T. brucei. However, only modest activity was observed in inhibition of proliferation of T. cruzi or P. falciparum.

Idioma originalEnglish
Páginas (desde-hasta)121-123
Número de páginas3
PublicaciónBioorganic and Medicinal Chemistry Letters
Volumen15
N.º1
DOI
EstadoPublished - ene 3 2005

Financiación

The Sandler Center for Basic Research in Parasitic Diseases and the National Institutes of Health.

Financiadores
National Institutes of Health (NIH)

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Medicine
    • Molecular Biology
    • Pharmaceutical Science
    • Drug Discovery
    • Clinical Biochemistry
    • Organic Chemistry

    Huella

    Profundice en los temas de investigación de 'Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain'. En conjunto forman una huella única.

    Citar esto